Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 1/2021

09.09.2020 | Review Article

Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review

verfasst von: Halimat Adedeji-Adenola, Manimbulu Nlooto

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background The challenges of under-reporting of adverse drug reactions have been identified as a major setback for the pharmacovigilance system worldwide. Direct reporting by health care consumers has been adopted in some developed and developing countries with a positive impact in improving pharmacovigilance activities through increased reporting rate. There are limited reports on direct reporting and its outcome in Africa. Aim of the review The study aimed to identify and present the available evidence on direct reporting of adverse drug reactions by healthcare consumers in Africa. Methods A review guided by Cochrane handbook was conducted. Electronic scientific databases such as PubMed, Cumulative Index to Nursing and Allied Health Literature, Embase and Cochrane Library were searched. Google scholar, general Google search engine, the website for the regulatory resources for Africa and World Health Organisation—Uppsala Monitoring were also searched for available guidelines, documents and publications. The review period was January 1992 to October 2019. The results were analysed descriptively. Results This study identified 16 African countries that have included healthcare consumers as eligible to report adverse drug reactions in their policy/guidelines. There is low awareness of healthcare consumers on pharmacovigilance system. Eight (8) out of thirty-six (36) African countries that are members of the World Health Organisation Programme for International Drug Monitoring have formally launched direct reporting by healthcare consumers which are 14.2% of African countries. There is a wide range of difference between the rate of adverse drug reactions report submitted by health care consumers as compared with healthcare workers. Paper form, text messages, telephone and web application-based reporting system have been used by different countries that have launched direct reporting. Poor infrastructure, low awareness and lack of a reporting culture are major challenges while the availability of common reporting methods is a potential opportunity of promoting direct reporting in African countries. Conclusions Few African countries have adopted and launched direct reporting. Reporting rate through direct methods is still relatively low when compared with reporting by healthcare workers. Published legal framework, policies, guidelines and studies on direct reporting are limited. Availability of a system and reporting method are opportunities to improve and overcome probable challenges.
Literatur
1.
Zurück zum Zitat Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.PubMed Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.PubMed
2.
Zurück zum Zitat Mudhaliar MR, Ghouse ISM, Gollapalli M, Bendala S, Pasumarthy R, Chinnakotla V. Responses of healthcare professionals to a standard self-administered questionnaire on pharmacovigilance and adverse drug reactions in South India. J Basic Clin Pharm. 2017;8(3):173–7. Mudhaliar MR, Ghouse ISM, Gollapalli M, Bendala S, Pasumarthy R, Chinnakotla V. Responses of healthcare professionals to a standard self-administered questionnaire on pharmacovigilance and adverse drug reactions in South India. J Basic Clin Pharm. 2017;8(3):173–7.
3.
Zurück zum Zitat Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl1):73. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl1):73.
4.
Zurück zum Zitat Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439.PubMedPubMedCentral Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439.PubMedPubMedCentral
8.
Zurück zum Zitat Al Dweik R, Yaya S, Stacey D, Kohen D. Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method study—study protocol. SpringerPlus. 2016;5(1):213. Al Dweik R, Yaya S, Stacey D, Kohen D. Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method study—study protocol. SpringerPlus. 2016;5(1):213.
9.
Zurück zum Zitat Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions. Drug Saf. 2009;32(11):1067–74.PubMed Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions. Drug Saf. 2009;32(11):1067–74.PubMed
10.
Zurück zum Zitat Amin MN, Khan TM, Dewan SMR, Islam MS, Moghal MR, Ming LC. Cross-sectional study exploring barriers to adverse drug reactions reporting in community pharmacy settings in Dhaka, Bangladesh. BMJ Open. 2016;6(8):e010912.PubMedPubMedCentral Amin MN, Khan TM, Dewan SMR, Islam MS, Moghal MR, Ming LC. Cross-sectional study exploring barriers to adverse drug reactions reporting in community pharmacy settings in Dhaka, Bangladesh. BMJ Open. 2016;6(8):e010912.PubMedPubMedCentral
11.
Zurück zum Zitat John LJ, Arifulla M, Cheriathu J, Sreedharan J. Reporting of adverse drug reactions: a study among cinicians. J Appl Pharm Sci 2012;2(6):135–39. John LJ, Arifulla M, Cheriathu J, Sreedharan J. Reporting of adverse drug reactions: a study among cinicians. J Appl Pharm Sci 2012;2(6):135–39.
12.
Zurück zum Zitat Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug Saf. 2009;32(1):19–31.PubMed Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug Saf. 2009;32(1):19–31.PubMed
13.
Zurück zum Zitat Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385–96.PubMed Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385–96.PubMed
14.
Zurück zum Zitat Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39(4):335–45.PubMedPubMedCentral Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39(4):335–45.PubMedPubMedCentral
15.
Zurück zum Zitat Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. BioMed Research International. 2016. Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. BioMed Research International. 2016.
16.
Zurück zum Zitat Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684–6.PubMed Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684–6.PubMed
17.
Zurück zum Zitat Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34.PubMedPubMedCentral Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34.PubMedPubMedCentral
18.
Zurück zum Zitat Ndagije HB, Nambasa V, Manirakiza L, Kusemererwa D, Kajungu D, Olsson S, et al. The burden of adverse drug reactions due to artemisinin-based antimalarial treatment in selected Ugandan health facilities: an active follow-up study. Drug Saf. 2018;41(8):753–65.PubMedPubMedCentral Ndagije HB, Nambasa V, Manirakiza L, Kusemererwa D, Kajungu D, Olsson S, et al. The burden of adverse drug reactions due to artemisinin-based antimalarial treatment in selected Ugandan health facilities: an active follow-up study. Drug Saf. 2018;41(8):753–65.PubMedPubMedCentral
19.
Zurück zum Zitat Aagaard L, Hansen EH. Consumers’ reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010;69(3):317–8.PubMedPubMedCentral Aagaard L, Hansen EH. Consumers’ reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010;69(3):317–8.PubMedPubMedCentral
20.
Zurück zum Zitat Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–56.PubMed Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–56.PubMed
21.
Zurück zum Zitat Wilson V, Amma V. Prospects of consumer-initiated adverse drug reaction reporting in cardiovascular pharmacovigilance. J Pract Cardiovasc Sci. 2015;1(1):54. Wilson V, Amma V. Prospects of consumer-initiated adverse drug reaction reporting in cardiovascular pharmacovigilance. J Pract Cardiovasc Sci. 2015;1(1):54.
22.
Zurück zum Zitat Jha N, Rathore DS, Shankar PR, Thapa BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. Aust Med J. 2014;7(4):191. Jha N, Rathore DS, Shankar PR, Thapa BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. Aust Med J. 2014;7(4):191.
23.
Zurück zum Zitat Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806–22.PubMedPubMedCentral Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806–22.PubMedPubMedCentral
24.
Zurück zum Zitat Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. JNCI J Natl Cancer Inst. 2009;101(23):1624–32.PubMed Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. JNCI J Natl Cancer Inst. 2009;101(23):1624–32.PubMed
25.
Zurück zum Zitat Hammond IW, Rich DS, Gibbs TG. Effect of consumer reporting on signal detection: using disproportionality analysis. Exp Opin Drug Saf. 2007;6(6):705–12. Hammond IW, Rich DS, Gibbs TG. Effect of consumer reporting on signal detection: using disproportionality analysis. Exp Opin Drug Saf. 2007;6(6):705–12.
26.
Zurück zum Zitat Van Grootheest K, de Graaf L. Consumer adverse drug reaction reporting. Drug Saf. 2003;26(4):211–7.PubMed Van Grootheest K, de Graaf L. Consumer adverse drug reaction reporting. Drug Saf. 2003;26(4):211–7.PubMed
27.
Zurück zum Zitat Van Hunsel F, Passier A, Van Grootheest K. Comparing patients’ and healthcare professionals’ ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67(5):558–64.PubMedPubMedCentral Van Hunsel F, Passier A, Van Grootheest K. Comparing patients’ and healthcare professionals’ ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67(5):558–64.PubMedPubMedCentral
28.
Zurück zum Zitat Bencheikh R, Squalli M, Ouled Errkhis R, Skalli S, Benkirane R, Khattabi A. Pharmacovigilance in Africa and contributing factors of its development. Conference paper. Rabat, Morocco. First African congress of Pharmacovigilance, 2013. Bencheikh R, Squalli M, Ouled Errkhis R, Skalli S, Benkirane R, Khattabi A. Pharmacovigilance in Africa and contributing factors of its development. Conference paper. Rabat, Morocco. First African congress of Pharmacovigilance, 2013.
29.
Zurück zum Zitat Ogar CK, Ibrahim A, Osakwe AI, Jajere F, Kigbu-Adekunle AA, Alonge K, et al. Pharmacovigilance rapid alert system for consumer reporting (PRASCOR): a look at its quantitative contribution to spontaneous reporting in Nigeria from August 2012 to February 2017. Pharm Med. 2018;32(2):131–41. Ogar CK, Ibrahim A, Osakwe AI, Jajere F, Kigbu-Adekunle AA, Alonge K, et al. Pharmacovigilance rapid alert system for consumer reporting (PRASCOR): a look at its quantitative contribution to spontaneous reporting in Nigeria from August 2012 to February 2017. Pharm Med. 2018;32(2):131–41.
30.
Zurück zum Zitat Margraff F, Bertram DJDS. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409–19.PubMed Margraff F, Bertram DJDS. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409–19.PubMed
31.
Zurück zum Zitat Avery T, Anderson C, Bond C, Fortnum H, Gifford A, Hannaford PC et al. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234. Avery T, Anderson C, Bond C, Fortnum H, Gifford A, Hannaford PC et al. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234.
32.
Zurück zum Zitat Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83(2):227–46.PubMed Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83(2):227–46.PubMed
33.
Zurück zum Zitat Saleh HA, Fourrier-Réglat A, Diogène E. Patient-centered pharmacovigilance: a review. Trop J Pharm Res. 2018;17(1):179–88. Saleh HA, Fourrier-Réglat A, Diogène E. Patient-centered pharmacovigilance: a review. Trop J Pharm Res. 2018;17(1):179–88.
34.
Zurück zum Zitat Inacio P, Gomes JJ, Airaksinen M, Cavaco A. Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients. Health Policy. 2018;122(3):263–8.PubMed Inacio P, Gomes JJ, Airaksinen M, Cavaco A. Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients. Health Policy. 2018;122(3):263–8.PubMed
35.
Zurück zum Zitat Watson S, Chandler RE, Taavola H, Härmark L, Grundmark B, Zekarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. 2018;41(2):203–12.PubMed Watson S, Chandler RE, Taavola H, Härmark L, Grundmark B, Zekarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. 2018;41(2):203–12.PubMed
36.
Zurück zum Zitat Jumo C. Health workers and hospital patients knowledge of pharmacovigilance in Sokoto, north-west Nigeria. Nigerian J Pharm Sci. 2012;11:31–40. Jumo C. Health workers and hospital patients knowledge of pharmacovigilance in Sokoto, north-west Nigeria. Nigerian J Pharm Sci. 2012;11:31–40.
37.
Zurück zum Zitat Sabblah GT, Darko DM, Mogtari H, Harmark L, van Puijenbroek E. Patients’ perspectives on adverse drug reaction reporting in a developing country: a case study from Ghana. Drug Saf. 2017;40(10):911–21.PubMed Sabblah GT, Darko DM, Mogtari H, Harmark L, van Puijenbroek E. Patients’ perspectives on adverse drug reaction reporting in a developing country: a case study from Ghana. Drug Saf. 2017;40(10):911–21.PubMed
38.
Zurück zum Zitat Jacobs TG, Ampadu HH, Hoekman J, Dodoo AN, Mantel-Teeuwisse AK. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health. 2018;18(1):1384.PubMedPubMedCentral Jacobs TG, Ampadu HH, Hoekman J, Dodoo AN, Mantel-Teeuwisse AK. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study. BMC Public Health. 2018;18(1):1384.PubMedPubMedCentral
39.
Zurück zum Zitat Adisa R, Adeniyi OR, Fakeye TO. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. Int J Clin Pharm. 2019;41:1062–1073.PubMed Adisa R, Adeniyi OR, Fakeye TO. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. Int J Clin Pharm. 2019;41:1062–1073.PubMed
40.
Zurück zum Zitat Agoro OO, Kibira SW, Freeman JV, Fraser HSF. Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation. J Am Med Inform Assoc. 2018;25(6):627–34.PubMed Agoro OO, Kibira SW, Freeman JV, Fraser HSF. Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation. J Am Med Inform Assoc. 2018;25(6):627–34.PubMed
41.
Zurück zum Zitat Darko DMaSG. Implementing patient reporting of adverse reactions in Africa WHO pharmaceuticals newsletter. 2016. Darko DMaSG. Implementing patient reporting of adverse reactions in Africa WHO pharmaceuticals newsletter. 2016.
42.
Zurück zum Zitat Zimbabwe MCAo. Zimbabwe National Pharmacovigilance Policy Handbook. In: Care MoHaC, editor. 2nd ed. Zimbabwe2016. p. 139. Zimbabwe MCAo. Zimbabwe National Pharmacovigilance Policy Handbook. In: Care MoHaC, editor. 2nd ed. Zimbabwe2016. p. 139.
43.
Zurück zum Zitat Pierce CE, de Vries ST, Bodin-Parssinen S, Härmark L, Tregunno P, Lewis DJ, et al. Recommendations on the Use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR. Drug Saf. 2019;42(4):477–89.PubMedPubMedCentral Pierce CE, de Vries ST, Bodin-Parssinen S, Härmark L, Tregunno P, Lewis DJ, et al. Recommendations on the Use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR. Drug Saf. 2019;42(4):477–89.PubMedPubMedCentral
44.
Zurück zum Zitat Pharmacy Boardof SierraLeone. Guideline For detecting and reporting adverse drug reactions. In: Sanitation MoHa, editor. Freetown: Pharmacy Board of SierraLeone; 2019. Pharmacy Boardof SierraLeone. Guideline For detecting and reporting adverse drug reactions. In: Sanitation MoHa, editor. Freetown: Pharmacy Board of SierraLeone; 2019.
46.
Zurück zum Zitat Kiberu VM, Mars M, Scott RE. Barriers and opportunities to implementation of sustainable e-Health programmes in Uganda: a literature review. Afr J Prim Health Care Fam Med. 2017;9(1):e1–10.PubMed Kiberu VM, Mars M, Scott RE. Barriers and opportunities to implementation of sustainable e-Health programmes in Uganda: a literature review. Afr J Prim Health Care Fam Med. 2017;9(1):e1–10.PubMed
47.
Zurück zum Zitat Isabalija SR, Mbarika V, Kituyi GM. A framework for sustainable implementation of e-medicine in transitioning countries. Int J Telemed Appl. 2013;2013:8. Isabalija SR, Mbarika V, Kituyi GM. A framework for sustainable implementation of e-medicine in transitioning countries. Int J Telemed Appl. 2013;2013:8.
49.
Zurück zum Zitat Elshafie S, Zaghloul I, Roberti AM. Pharmacovigilance in developing countries (part I): importance and challenges. 2018;40(4):758–763.PubMed Elshafie S, Zaghloul I, Roberti AM. Pharmacovigilance in developing countries (part I): importance and challenges. 2018;40(4):758–763.PubMed
50.
Zurück zum Zitat Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, Hopkins H, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health. 2008;13(9):1143–52.PubMed Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, Hopkins H, et al. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health. 2008;13(9):1143–52.PubMed
51.
Zurück zum Zitat MedicinesControlCouncil. reporting of post-marketing adverse drug reactions to human medicinal products in South Africa. In: Health, Do, editors South Africa 2014. p. 20. MedicinesControlCouncil. reporting of post-marketing adverse drug reactions to human medicinal products in South Africa. In: Health, Do, editors South Africa 2014. p. 20.
52.
Zurück zum Zitat Jha N, Rathore DS, Shankar PR, Thapa BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. Aust Med J. 2014;7(4):191–5. Jha N, Rathore DS, Shankar PR, Thapa BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. Aust Med J. 2014;7(4):191–5.
53.
Zurück zum Zitat Alshakka M, Jha N, Algefri S, Ibrahim MIM, Hassali MA, Abdorabbo A, et al. Problems and challenges faced in consumer reporting of adverse drug reactions in developing countries—a case study of Yemen, Nepal and Malaysia. Indian J Pharm Biol Res. 2014;2(3):37. Alshakka M, Jha N, Algefri S, Ibrahim MIM, Hassali MA, Abdorabbo A, et al. Problems and challenges faced in consumer reporting of adverse drug reactions in developing countries—a case study of Yemen, Nepal and Malaysia. Indian J Pharm Biol Res. 2014;2(3):37.
55.
Zurück zum Zitat WEBRADR. Mobile App pilot in African countries. 2017. Accessed 28 Sept 2018. WEBRADR. Mobile App pilot in African countries. 2017. Accessed 28 Sept 2018.
56.
Zurück zum Zitat de Langen J, van Hunsel F, Passier A, de Jong-van den Berg L, van Grootheest K. Adverse drug reaction reporting by patients in The Netherlands three years of experience. Drug Saf. 2008;31(6):515–24.PubMed de Langen J, van Hunsel F, Passier A, de Jong-van den Berg L, van Grootheest K. Adverse drug reaction reporting by patients in The Netherlands three years of experience. Drug Saf. 2008;31(6):515–24.PubMed
57.
Zurück zum Zitat Li H, Guo X-J, Ye X-F, Jiang H, Du W-M, Xu J-F, et al. Adverse drug reactions of spontaneous reports in shanghai pediatric population. PLoS One. 2014;9(2):e89829.PubMedPubMedCentral Li H, Guo X-J, Ye X-F, Jiang H, Du W-M, Xu J-F, et al. Adverse drug reactions of spontaneous reports in shanghai pediatric population. PLoS One. 2014;9(2):e89829.PubMedPubMedCentral
58.
Zurück zum Zitat Härmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug Saf. 2015;38(4):337–47.PubMed Härmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug Saf. 2015;38(4):337–47.PubMed
59.
Zurück zum Zitat Service MoHaS. Namibia-national-guidelines-for-medicine-safety-surveillance. National Guidelines for Medicine Safety Surveillance. Therapeutics Information and Pharmacovigilance Center, TIPC; 2011. p. 22. Service MoHaS. Namibia-national-guidelines-for-medicine-safety-surveillance. National Guidelines for Medicine Safety Surveillance. Therapeutics Information and Pharmacovigilance Center, TIPC; 2011. p. 22.
60.
Zurück zum Zitat van Hunsel F, Härmark L, Pal S, Olsson S van, Grootheest KJDs. Experiences with adverse drug reaction reporting by patients. Drug Saf. 2012;35(1):45–60.PubMed van Hunsel F, Härmark L, Pal S, Olsson S van, Grootheest KJDs. Experiences with adverse drug reaction reporting by patients. Drug Saf. 2012;35(1):45–60.PubMed
61.
Zurück zum Zitat Yamamoto M, Kubota K, Okazaki M, Dobashi A, Hashiguchi M, Doi H, et al. Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in Japan. Patient Prefer Adherence. 2015;9:173–84.PubMedPubMedCentral Yamamoto M, Kubota K, Okazaki M, Dobashi A, Hashiguchi M, Doi H, et al. Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in Japan. Patient Prefer Adherence. 2015;9:173–84.PubMedPubMedCentral
62.
Zurück zum Zitat Dodoo AN. Active safety surveillance in Africa: pragmatism and agility. Drug Saf. 2018;41(8):731–3.PubMed Dodoo AN. Active safety surveillance in Africa: pragmatism and agility. Drug Saf. 2018;41(8):731–3.PubMed
Metadaten
Titel
Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review
verfasst von
Halimat Adedeji-Adenola
Manimbulu Nlooto
Publikationsdatum
09.09.2020
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 1/2021
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01141-x

Weitere Artikel der Ausgabe 1/2021

International Journal of Clinical Pharmacy 1/2021 Zur Ausgabe

ACKNOWLEDGEMENT

Thank You Reviewers

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.